Research ExplorerPublicationsEducational Needs for Physicians

Educational Needs for Physicians

Standard

Educational Needs for Physicians. / Kröger, Nicolaus; Gribben, John; Sánchez-Ortega, Isabel.

The EBMT/EHA CAR-T Cell Handbook. ed. / Nicolaus Kröger; John Gribben; Christian Chabannon; Ibrahim Yakoub-Agha; Hermann Einsele. 1. ed. Cham : Springer International Publishing, 2022. p. 203-206.

Research output: SCORING: Contribution to book/anthology › Chapter › Research

Harvard

Kröger, N, Gribben, J & Sánchez-Ortega, I 2022, Educational Needs for Physicians. in N Kröger, J Gribben, C Chabannon, I Yakoub-Agha & H Einsele (eds), The EBMT/EHA CAR-T Cell Handbook. 1 edn, Springer International Publishing, Cham, pp. 203-206. https://doi.org/10.1007/978-3-030-94353-0_39

APA

Kröger, N., Gribben, J., & Sánchez-Ortega, I. (2022). Educational Needs for Physicians. In N. Kröger, J. Gribben, C. Chabannon, I. Yakoub-Agha, & H. Einsele (Eds.), The EBMT/EHA CAR-T Cell Handbook (1 ed., pp. 203-206). Springer International Publishing. https://doi.org/10.1007/978-3-030-94353-0_39

Vancouver

Kröger N, Gribben J, Sánchez-Ortega I. Educational Needs for Physicians. In Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors, The EBMT/EHA CAR-T Cell Handbook. 1 ed. Cham: Springer International Publishing. 2022. p. 203-206 https://doi.org/10.1007/978-3-030-94353-0_39

Bibtex

@inbook{eccd3c7e26ef4d649d67e4a349479d55,
title = "Educational Needs for Physicians",
abstract = "CAR-T cells are novel therapies associated with promising and potentially curative outcomes in patients with high-risk relapsed disease. In Europe, there are currently three approved products (tisagenlecleucel, axicabtagene ciloleucel, and brexucabtagene autoleucel) for patients with acute lymphoblastic leukaemia, aggressive B-cell lymphoma, and mantle cell lymphoma, although expanded haematologic and nonhaematologic indications are expected soon.",
author = "Nicolaus Kr{\"o}ger and John Gribben and Isabel S{\'a}nchez-Ortega",
year = "2022",
doi = "10.1007/978-3-030-94353-0_39",
language = "English",
isbn = "978-3-030-94352-3",
pages = "203--206",
editor = "Nicolaus Kr{\"o}ger and John Gribben and Christian Chabannon and Ibrahim Yakoub-Agha and Hermann Einsele",
booktitle = "The EBMT/EHA CAR-T Cell Handbook",
publisher = "Springer International Publishing",
address = "Switzerland",
edition = "1",

}

RIS

TY - CHAP

T1 - Educational Needs for Physicians

AU - Kröger, Nicolaus

AU - Gribben, John

AU - Sánchez-Ortega, Isabel

PY - 2022

Y1 - 2022

N2 - CAR-T cells are novel therapies associated with promising and potentially curative outcomes in patients with high-risk relapsed disease. In Europe, there are currently three approved products (tisagenlecleucel, axicabtagene ciloleucel, and brexucabtagene autoleucel) for patients with acute lymphoblastic leukaemia, aggressive B-cell lymphoma, and mantle cell lymphoma, although expanded haematologic and nonhaematologic indications are expected soon.

AB - CAR-T cells are novel therapies associated with promising and potentially curative outcomes in patients with high-risk relapsed disease. In Europe, there are currently three approved products (tisagenlecleucel, axicabtagene ciloleucel, and brexucabtagene autoleucel) for patients with acute lymphoblastic leukaemia, aggressive B-cell lymphoma, and mantle cell lymphoma, although expanded haematologic and nonhaematologic indications are expected soon.

U2 - 10.1007/978-3-030-94353-0_39

DO - 10.1007/978-3-030-94353-0_39

M3 - Chapter

SN - 978-3-030-94352-3

SP - 203

EP - 206

BT - The EBMT/EHA CAR-T Cell Handbook

A2 - Kröger, Nicolaus

A2 - Gribben, John

A2 - Chabannon, Christian

A2 - Yakoub-Agha, Ibrahim

A2 - Einsele, Hermann

PB - Springer International Publishing

CY - Cham

ER -